Despite the success of anti-HER2 therapies, patients with HER2 positive breast cancer frequently present with either primary or acquired resistance to these agents. Thus, novel therapeutic strategies that can overcome such resistance are urgently needed.
Introduction
Amplification of the receptor tyrosine kinase (RTK) HER2 has been reported in approximately one fourth of human breast tumors, and its overexpression is associated with a more aggressive phenotype and poor clinical outcome (1, 2) . There are two main therapeutic strategies employed to target HER2 positive cells: the first are monoclonal antibodies targeting the extracellular domain of the receptor (trastuzumab, pertuzumab); the second small molecule ATP competitors that inhibit the
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Here we demonstrate that lapatinib in combination with INK-128 profoundly inhibits both the PI3K/Akt/mTOR and ERK pathways resulting in apoptosis in vitro and in vivo tumor shrinkage in all models tested. Importantly, no signs of toxicity were observed in our in vivo experiments.
These data indicate that it is possible to achieve durable regressive responses in tumor models refractory to anti-HER2 therapy by inhibiting both the PI3K/Akt/mTOR and HER2 pathways without signs of toxicity.
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Author Manuscript Published OnlineFirst on March 8, 2012; DOI: 10.1158/1078-0432.CCR- out in a FACScalibur cytometer using the Cell Quest software (BD Biosciences, NJ, USA).
Establishment of tumor xenografts in nude mice
Mice were maintained and treated in accordance with institutional guidelines of Vall d'Hebron University Hospital Care and Use Committee. Six week old female athymic nude HsdCpb:NMRI-Foxn1nu mice were purchased from Harlan Laboratories (Italy).
Mice were housed in air-filtered laminar flow cabinets with a 12-h light cycle and food and water ad libitum. were supplemented with 1μM 17β-estradiol (Sigma) in their drinking water, an amount demonstrated to be sufficient to reach serum levels and uterine growth in ovariectomized female mice similar to the ones obtained with other mechanisms of 17β-estradiol supplementation (39, 40) . Upon xenograft growth, tumor tissue was reimplanted into recipient mice, which were randomized upon implant growth.
MDA-MB361 or

In vivo treatment study
Cell line-derived xenografts: growth took approximately 2-3 weeks prior to animal randomization at a volume of 200-300 mm 3 . Animals were randomized to 4 groups, consisting of 6-9 mice per group. Patient-derived xenografts: growth of subcutaneous implants took approximately three weeks prior to animal randomization at a volume of 100-200 mm 3 . Animals were randomized into 5 groups, consisting of 6-8 mice per group.
Animals were treated with INK-128 6QD/W (0.3 mg/kg in 5% NMP, 15% PVP in water, oral gavage), lapatinib 6QD/W (150 mg/kg in 0.5% HPMC, 0.1% Tween 80 in water, oral gavage), or trastuzumab 2QD/W (10mg/kg, in water, intraperitoneal injection).
Tumor xenografts were measured with calipers and tumor volumes were determined using the formula: (length × width 2 ) × (π/6). At the end of the experiment, animals were euthanized using CO 2 inhalation. Tumor volumes are plotted as means ± SE.
For western blotting, lysates from two different tumors derived from each treatment were processed as described above.
Statistical analysis
Two-way ANOVA with Bonferroni post-test was performed using GraphPad Prism 
Results
In vitro activity of anti-HER2 and mTORC1/2 therapy in HER2 positive cell lines
In order to test the effects of dual mTORC1/2 blockade in HER2 positive cells, we screened a panel of seven HER2 positive breast cancer cell lines for both lapatinib and INK-128 sensitivity using an ATP-based cell viability assay (Fig 1A and 1B) . After six days of treatment, we observed varying sensitivity to lapatinib, with SKBR-3 and BT474 cells being significantly more sensitive than were MDA-MB361, MDA-MB453, KPL4, HCC-1954 and JIMT1 cell lines (Fig 1A) . Moreover, the latter five cell lines were completely refractory to the antiproliferative effects of trastuzumab (data not shown).
Given these striking differences in anti-HER2 sensitivity, we defined BT474 and SKBR-3 cell lines as sensitive and MDA-MB361, MDA-MB453, KPL4, HCC1954 and JIMT1 cell lines as resistant (Fig 1A) . While we acknowledge that lower lapatinib IC50s have been previously reported for MDA-MB361 cells (36, 41, 42) all five resistant cell lines tested were found to harbor activating alterations of the PI3K pathway (PI3K mutations, low/loss of expression of PTEN or both), whereas the two sensitive cell lines did not (with the exception of the non-activating K111N PIK3CA mutation (43) present in BT474 cells). A detailed biochemical analysis of the sensitive cell lines confirmed that both the PI3K/Akt/mTOR and ERK pathways were profoundly suppressed at low concentrations of lapatinib ( Supplementary Fig 1) . In contrast, the same molecular markers, especially the ones related to the PI3K/Akt/mTOR axis, were only moderately affected by HER2 inhibition in the resistant cells ( Supplementary Fig 2) . When treated with INK-128, the proliferation of all seven cell lines was significantly inhibited at low nanomolar ranges (Fig 1B) .
In analyzing these data, we reasoned that the use of lapatinib in combination with a dual mTORC1/2 inhibitor, such as INK-128, would result in enhanced antiproliferative activity. Possible synergism between lapatinib and INK-128 in lapatinib-resistant cell lines was evaluated using the combination index (CI) (37) . In all five cell lines tested (Table 1 and Supplementary Fig 3A) . In particular, the best efficacy of this combination was observed at concentrations between 0.1 and 10nM, depending on the cell lines ( Supplementary Fig 3B) .
Dual PI3K/mTOR and ERK suppression combining INK-128 with lapatinib
It has been previously described by our group and others that PI3K/Akt/mTOR pathway inhibition may result in the activation of compensatory pathways that could reduce the antiproliferative activity of these inhibitors (28, 31, 44-46). As expected, we observed reproducible increases in HER2/HER3 phosphorylation following INK-128 treatment in all the tested cell lines (Fig 2 and data not shown). This phenomenon coincided with ERK activation, which was more evident at the 2h timepoint.
The combination of lapatinib with INK-128, tested in three lapatinib/trastuzumabresistant cell lines, was demonstrated to effectively prevent HERs phosphorylation, to suppress PI3K/Akt/mTOR signaling, and to limit ERK phosphorylation consequent to INK-128 treatment (Fig 2) .
Cell cycle analysis and apoptosis in trastuzumab/lapatinib resistant cell lines treated with lapatinib and INK-128
The in vitro synergistic effects summarized in Table 1 
absence of toxicity (defined as weight loss or lethargy) after 80 days of continuous administration with the drugs (Fig 4C) . Deriving from a patient who became refractory to trastuzumab-based therapy, we first confirmed that this PDX model was unresponsive to trastuzumab therapy ( Supplementary Fig 8) . We then tested the tumor activity of lapatinib, INK-128 and the combination of both. As shown in Fig 5A, combination therapy demonstrated significant inhibition of both PI3K/Akt/mTOR and ERK pathways (Fig 5B) .
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